Patents by Inventor Elena Kistanova

Elena Kistanova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC CLOTTING FACTORS
    Publication number: 20220135959
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Application
    Filed: October 7, 2021
    Publication date: May 5, 2022
    Inventors: Joe SALAS, Elena KISTANOVA, Vu Phong HONG, Adam R. MEZO, Robert T. PETERS
  • Chimeric clotting factors
    Patent number: 11168316
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Bioverativ Therapeutics, Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters
  • CHIMERIC CLOTTING FACTORS
    Publication number: 20190225957
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 25, 2019
    Applicant: Bioverativ Therapeutics, Inc.
    Inventors: Joe SALAS, Elena KISTANOVA, Vu Phong HONG, Adam R. MEZO, Robert T. PETERS
  • Chimeric clotting factors
    Patent number: 10202595
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 12, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Meso, Robert T. Peters
  • CHIMERIC CLOTTING FACTORS
    Publication number: 20150353911
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 10, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters